Skip to main content

Table 5 The representative completed clinical trials about osteosarcoma

From: A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019

No. Study Title Conditions Interventions
1 Investigation of [6R] 5,10-methylenetetrahydrofolate as Rescue Therapy for Osteosarcoma Patients Treated with HDMTX Osteosarcoma Drug: Calcium Folinate and [6R] 5,10-methylenetetrahydrofolate
2 Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma Osteosarcoma Drug: Cisplatin, Doxorubicin and Methotrexate
3 Glembatumumab Vedotin in Treating Patients with Recurrent or Refractory Osteosarcoma Recurrent Osteosarcoma Drug: Glembatumumab Vedotin
Other: Laboratory Biomarker Analysis
And Pharmacological Study
4 Eribulin Mesylate in Treating Patients with Recurrent or Refractory Osteosarcoma Recurrent Osteosarcoma Drug: Eribulin Mesylate
Other: Pharmacological Study
5 Chemotherapy for Patients with Osteosarcoma Osteosarcoma Drug: Pemetrexed
6 Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung Osteosarcoma Metastatic Drug: Cisplatin liposomal
7 Preventing Nephrotoxicity and Ototoxicity from Osteosarcoma Therapy Osteosarcoma Drug: Pantoprazole and High-dose methotrexate infusion duration
8 Inhaled Sargramostim in Treating Patients with First Pulmonary (Lung) Recurrence of Osteosarcoma Metastatic Cancer
Sarcoma
Biological: sargramostim
Procedure: conventional surgery
9 Differentiation of Bone Sarcomas and Osteomyelitis with Ferumoxytol-Enhanced MRI Bone Cancer
Osteosarcoma
Drug: Feraheme
Procedure: Magnetic Resonance Imaging (MRI) scan
10 Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma Sarcoma Drug: Dacarbazine
11 A Study of Bevacizumab in Combination with Chemotherapy for Treatment of Osteosarcoma Osteosarcoma Biological: Bevacizumab
Drug: Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, etoposide
Procedure: Surgery
Radiation: Radiotherapy
12 A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma Osteosarcoma Drug: Cyclophosphamide and Sirolimus
13 Samarium Sm 153 and Stem Cell Transplant Followed by Radiation Therapy Patients with Osteosarcoma Sarcoma Biological: filgrastim
Drug: ifosfamide
Procedure: peripheral blood stem cell transplantation
Radiation: Sm-EDTMP (low dose) and Sm-EDTMP (higher dose)
14 Gemcitabine and Docetaxel in Treating Patients with Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing’s Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma Sarcoma Biological: filgrastim and pegfilgrastim
Drug: docetaxel and gemcitabine hydrochloride
Genetic: microarray analysis
Other: laboratory biomarker analysis and pharmacokinetic study
15 Temsirolimus and Cixutumumab in Treating Patients with Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma Metastatic Osteosarcoma Recurrent Osteosarcoma Biological: Cixutumumab
Other: Laboratory Biomarker Analysis
Drug: Temsirolimus
16 Therapeutic Angiotensin-(1–7) in Treating Patients with Metastatic Sarcoma That Cannot Be Removed by Surgery Bone Cancer
Metastatic Osteosarcoma
Drug: therapeutic angiotensin-(1–7)
Other: laboratory biomarker analysis
17 Sorafenib in Treating Patients with Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) Metastatic Osteosarcoma
Recurrent Osteosarcoma
Drug: sorafenib tosylate
Procedure: therapeutic conventional surgery, computed tomography and dynamic contrast-enhanced magnetic resonance imaging
Other: laboratory biomarker analysis and pharmacological study
18 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients with Recurrent Sarcoma Sarcoma Drug: temsirolimus plus liposomal doxorubicin
19 A Study of Pemetrexed in Children with Recurrent Cancer Osteosarcoma Drug: pemetrexed
20 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients with Advanced or Metastatic Sarcoma Metastatic Osteosarcoma Recurrent Osteosarcoma Drug: Gamma-Secretase Inhibitor RO4929097 and Vismodegib
Other: Laboratory Biomarker Analysis and Pharmacological Study
21 Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients with Recurrent/ Refractory Solid Tumors Osteogenic
Sarcoma
Drug: nab-paclitaxel
22 Cixutumumab and Temsirolimus in Treating Younger Patients with Recurrent or Refractory Sarcoma Recurrent Osteosarcoma Biological: Cixutumumab
Other: Laboratory Biomarker Analysis
Drug: Temsirolimus
23 Cixutumumab in Treating Patients with Relapsed or Refractory Solid Tumors Recurrent Osteosarcoma Biological: cixutumumab
Other: laboratory biomarker analysis
24 Alisertib in Treating Young Patients with Recurrent or Refractory Solid Tumors or Leukemia Recurrent Osteosarcoma Drug: Alisertib
Other: Laboratory Biomarker Analysis and Pharmacological Study
25 Depsipeptide (Romidepsin) in Treating Patients with Metastatic or Unresectable Soft Tissue Sarcoma Adult Extraskeletal Osteosarcoma Drug: romidepsin
26 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma Relapsed Ewing Sarcoma
Refractory Ewing Sarcoma
Drug: Linsitinib
27 Olaparib in Adults with Recurrent/Metastatic Ewing’s Sarcoma Ewing’s Sarcoma Drug: Olaparib
28 Cytarabine in Treating Young Patients with Recurrent or Refractory Ewing’s Sarcoma Sarcoma Drug: cytarabine
29 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients with Newly-Diagnosed Metastatic Ewing’s Sarcoma Family of Tumors Sarcoma Drug: celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, MESNA and Filgrastim
Procedure: conventional surgery
Radiation: radiation therapy
30 Sunitinib in Treating Patients with Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Sarcoma Drug: sunitinib malate
31 Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide with or Without Bevacizumab in Treating Young Patients with Refractory or First Recurrent Extracranial Ewing Sarcoma Ewing Sarcoma of Bone Drug: topotecan hydrochloride, vincristine sulfate and cyclophosphamide
Biological: bevacizumab
32 Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients with Relapsed/Refractory Ewing’s Sarcoma and Neuroblastoma Neuroblastoma
Sarcoma
Drug: Cyclophosphamide, Topotecan, and Bevacizumab
33 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Ewing’s Sarcoma Biological: IMC-A12 (cixutumumab)
34 Trial of Dasatinib in Advanced Sarcomas Sarcoma, Ewing’s Drug: Dasatinib
35 Trabectedin in Treating Young Patients with Recurrent or Refractory Soft Tissue Sarcoma or Ewing’s Family of Tumors Recurrent Ewing Sarcoma Drug: trabectedin
Other: pharmacological study
36 A Pilot Study of Autologous T-Cell Transplantation with Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Ewing’s Sarcoma
Rhabdomyosarcoma
Biological: therapeutic autologous dendritic cells
Drug: indinavir sulfate
Procedure: peripheral blood stem cell transplantation
37 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients with Sarcoma Sarcoma Biological: filgrastim
Drug: cisplatin, doxorubicin hydrochloride, ifosfamide and melphalan
Procedure: peripheral blood stem cell transplantation
38 Study Of CP-751,871 In Patients with Ewing’s Sarcoma Family of Tumors Ewing’s Sarcoma Drug: CP-751,871
39 Arsenic Trioxide in Treating Patients with Advanced Neuroblastoma or Other Childhood Solid Tumors Sarcoma Drug: arsenic trioxide
40 Plerixafor After Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma Adult Medulloblastoma Radiation: radiation therapy
Drug: temozolomide and plerixafor
Other: laboratory biomarker analysis and pharmacological study
41 Therapy to Treat Ewing’s Sarcoma, Rhabdomyosarcoma or Neuroblastoma Sarcoma Drug: Tumor Purged/CD25 Depleted Lymphocytes and rhIL-7
Biological: Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine and Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine